Lumigan(bimatoprost)
Bimatoprost, Durysta, Ganfort, Latisse, Lumigan (bimatoprost) is a small molecule pharmaceutical. Bimatoprost was first approved as Lumigan on 2001-03-16. It is used to treat open-angle glaucoma in the USA. It has been approved in Europe to treat ocular hypertension and open-angle glaucoma. The pharmaceutical is active against prostaglandin F2-alpha receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| eye diseases | D005128 |
Trade Name
FDA
EMA
Bimatoprost, Durysta, Latisse, Lumigan, Zolymbus (discontinued: Bimatoprost, Lumigan)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| bimatoprost | ANDA | 2026-01-09 |
| durysta | New Drug Application | 2024-10-16 |
| latisse | New Drug Application | 2024-07-01 |
| lumigan | New Drug Application | 2024-06-20 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| open-angle glaucoma | EFO_0004190 | D005902 | H40.1 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
BIMATOPROST, DURYSTA, ABBVIE | |||
| 2023-03-04 | NP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Bimatoprost, Durysta, Abbvie | |||
| 9492316 | 2034-10-31 | DP | |
| 9980974 | 2034-10-31 | U-2759 | |
| 8629185 | 2031-07-15 | DS, DP | |
| 7799336 | 2029-04-24 | DP | |
| 8206737 | 2027-04-07 | U-2759 | |
| 9149428 | 2026-12-19 | DP | |
| 10441543 | 2026-12-19 | DP | |
| 8673341 | 2025-02-19 | U-2759 | |
| 10398707 | 2024-04-30 | U-2759 | |
| Bimatoprost, Lumigan, Abbvie | |||
| 7851504 | 2027-06-13 | DS, DP | |
| 8278353 | 2025-03-16 | DP | |
| 8299118 | 2025-03-16 | U-1295 | |
| 8309605 | 2025-03-16 | U-1293, U-1294 | |
| 8338479 | 2025-03-16 | DP | U-1295 |
| 8524777 | 2025-03-16 | U-1235 | |
| 8586630 | 2025-03-16 | U-1458 | |
| 8772338 | 2025-03-16 | DP | U-1528 |
| 8933120 | 2025-03-16 | DP | |
| 8933127 | 2025-03-16 | DP | |
| 9155716 | 2025-03-16 | DP | U-1528 |
| 9241918 | 2025-03-16 | DP | U-1814 |
| Bimatoprost, Latisse, Abbvie | |||
| 8101161 | 2024-05-25 | U-1217, U-1218 | |
| 8038988 | 2023-08-25 | DS, DP | U-1208 |
| 8263054 | 2023-01-15 | U-1277 | |
| 8632760 | 2023-01-15 | U-1487 | |
| 8758733 | 2023-01-15 | U-1487 | |
| 8986715 | 2023-01-15 | U-1217 | |
| 9216183 | 2023-01-15 | U-1487 | |
| 9226931 | 2023-01-15 | U-1799 | |
HCPCS
Code | Description |
|---|---|
| J7351 | Injection, bimatoprost, intracameral implant, 1 microgram |
Clinical
Clinical Trials
174 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glaucoma | D005901 | EFO_0000516 | H40 | 4 | 18 | 21 | 40 | 25 | 104 |
| Ocular hypertension | D009798 | EFO_1001069 | H40.0 | 6 | 20 | 26 | 34 | 19 | 99 |
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | 4 | 15 | 15 | 21 | 19 | 70 |
| Hypertension | D006973 | EFO_0000537 | I10 | 3 | 14 | 16 | 17 | 10 | 57 |
| Hypotrichosis | D007039 | — | — | — | 1 | 6 | 6 | 2 | 15 |
| Alopecia | D000505 | — | L64 | 4 | 5 | — | 1 | 2 | 11 |
| Alopecia areata | D000506 | EFO_0004192 | L63 | 4 | 4 | — | 1 | 1 | 9 |
| Cataract | D002386 | EFO_0001059 | H26.9 | 1 | 2 | 2 | 1 | 2 | 7 |
| Graves ophthalmopathy | D049970 | EFO_1001466 | — | 1 | — | 1 | 2 | — | 4 |
| Vitiligo | D014820 | EFO_0004208 | L80 | 1 | 1 | — | 2 | — | 4 |
Show 9 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thyroid diseases | D013959 | — | E00-E07 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | 1 | — | — | — | 1 |
| Headache disorders | D020773 | EFO_0009550 | G44 | — | 1 | — | — | — | 1 |
| Headache | D006261 | — | R51 | — | 1 | — | — | — | 1 |
| Hypertrophic cicatrix | D017439 | — | L91.0 | — | 1 | — | — | — | 1 |
| Cicatrix | D002921 | — | L90.5 | — | 1 | — | — | — | 1 |
| Pigmentation disorders | D010859 | — | L81.9 | — | 1 | — | — | — | 1 |
| Hypopigmentation | D017496 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
| Cutis laxa | D003483 | — | Q82.8 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Retinal detachment | D012163 | EFO_0005773 | H33.2 | — | — | — | — | 1 | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 1 | 1 |
| Hypertrichosis | D006983 | — | L68 | — | — | — | — | 1 | 1 |
| Angle-closure glaucoma | D015812 | — | — | — | — | — | — | 1 | 1 |
| Corneal diseases | D003316 | — | H18.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Bimatoprost |
| INN | bimatoprost |
| Description | Bimatoprost is a monocarboxylic acid amide. It has a role as an antiglaucoma drug and an antihypertensive agent. |
| Classification | Small molecule |
| Drug class | prostaglandins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 155206-00-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200963 |
| ChEBI ID | 51230 |
| PubChem CID | 5311027 |
| DrugBank | DB00905 |
| UNII ID | QXS94885MZ (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
AKR1C3
AKR1C3
Organism
Homo sapiens
Gene name
AKR1C3
Gene synonyms
DDH1, HSD17B5, KIAA0119, PGFS
NCBI Gene ID
Protein name
aldo-keto reductase family 1 member C3
Protein synonyms
17-beta-HSD 5, 17-beta-hydroxysteroid dehydrogenase type 5, 3-alpha hydroxysteroid dehydrogenase, type II, 3-alpha-HSD type 2, 3-alpha-HSD type II, brain, 3-alpha-hydroxysteroid dehydrogenase type 2, Chlordecone reductase homolog HAKRb, DD-3, DD3, Dihydrodiol dehydrogenase 3, Dihydrodiol dehydrogenase type I, dihydrodiol dehydrogenase X, HA1753, indanol dehydrogenase, PGFS, Prostaglandin F synthase, Testosterone 17-beta-dehydrogenase 5, trans-1,2-dihydrobenzene-1,2-diol dehydrogenase, type IIb 3-alpha hydroxysteroid dehydrogenase
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Bimatoprost
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,559 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
22,285 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use